Kurma Partners is a venture capital firm based in Paris and Munich that specializes in funding biopharma and digital diagnostics companies. Kurma Partners manages more than €400 million, a large part of which goes towards setting up companies based on innovative academic research.
"Our collaboration with the Institut Pasteur began when Kurma was first set up back in 2009, with a cooperation agreement to promote the industrial development of innovations from the Institut Pasteur's laboratories.
This cooperation continued when we launched our Kurma Diagnostics I fund (the first European fund specializing in digital diagnostics solutions) and Kurma Biofund III (in 2019).
In the coming years, we aim to prioritize the emergence of new companies spun off from the Institut Pasteur, while also encouraging our startups to develop further links with the Institut Pasteur's scientists.
Several ambitious startups have already been launched as a result of collaboration between the Institut Pasteur's scientists and Kurma's investors, including Cellectis, DNA Script, Pathoquest and KDx Acceleration.
What interests us with the Institut Pasteur is the remarkable capability for innovation demonstrated by its research teams, which have been at the forefront of many major discoveries in fields such as infection, immunology and molecular biology.
Our hope is that through our collaboration, we will help harness even more innovations from the Institut Pasteur's research and encourage the startup community to develop further links with the Institut Pasteur! "
Thierry Laugel, Rémi Droller and Vanessa Malier, Managing Partners of Kurma Partners